Innovations in drug development, including an enhanced focus on targeted therapeutics and advanced screening methods, have led to an increase in the number of highly potent APIs (HPAPIs); in turn, this can deliver drugs requiring lower doses with fewer side effects. But safely working with these compounds during development and manufacturing can be a challenge, requiring stringent processes and specialized, qualified equipment to ensure containment, provide operator safety, and minimize risk of cross-contamination. The facilities working with HPAPIs need to have robust capabilities in chemical synthesis, purification, and analysis to properly support these drug product programs.
Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy